Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
American Journal of Hematology|December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsSylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Leukemia|September 16, 2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemiaRémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Pageof 5